Evaluating M2BPGi as a Marker for Liver Fibrosis in Patients with Chronic Hepatitis B

Background The accurate evaluation of liver fibrosis is crucial for the treatment and follow up of chronic hepatitis B (CHB) patients. Aim We examined the efficiency of serum Mac-2 Binding Protein Glycosylation isomer (M2BPGi) in diagnosing liver fibrosis stages in CHB patients. Methods A cross-sect...

Full description

Saved in:
Bibliographic Details
Published in:Digestive diseases and sciences 2023-12, Vol.68 (12), p.4407-4417
Main Authors: Bui, Hoang Huu, Nguyen, Suong Thi-Bang, Phan, Sang The, Nguyen, Khue Minh, Nguyen, Chuong Dinh
Format: Article
Language:English
Subjects:
Biochemistry
Care and treatment
Fibrosis
Gastroenterology
Hepatitis
Hepatitis B
Hepatology
Liver
Liver cirrhosis
Medical centers
Medicine
Medicine & Public Health
Oncology
Original Article
Protein binding
Transplant Surgery
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background The accurate evaluation of liver fibrosis is crucial for the treatment and follow up of chronic hepatitis B (CHB) patients. Aim We examined the efficiency of serum Mac-2 Binding Protein Glycosylation isomer (M2BPGi) in diagnosing liver fibrosis stages in CHB patients. Methods A cross-sectional study was conducted on 177 adult CHB patients visiting the University Medical Center Ho Chi Minh City, Vietnam between October 2019 and December 2021. M2BPGi, ARFI, APRI, and FIB-4 were tested against FibroScan® for sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV). The optimal M2BPGi cut-off values were identified based on the area under the receiver operating characteristic (AUROC) curve. Results There was a strong agreement between M2BPGi and FibroScan® ( r  = 0.77, P  
ISSN:0163-2116
1573-2568
DOI:10.1007/s10620-023-08143-5